ArticleIndian pacing and electrophysiology journal
Usefulness of aVR sign as a predictor of sudden cardiac death or appropriate ICD shocks in Brugada syndrome: A systematic review and meta-analysis of cohort studies.
Article in Indian pacing and electrophysiology journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brugada syndrome in a boy aged 15 months.HeartRhythm case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral electrocardiograph markers are proposed as predictors of life-threatening arrhythmia in Brugada Syndrome, including the aVR sign. However, results of previous studies were inconsistent. Therefore, we aim to determine whether the aVR sign can predict sudden cardiac death in BrS patients.
methodsWe extracted data from PubMed, Cochrane, and EBSCO using MeSH keywords "Brugada syndrome, sudden cardiac death, arrhythmia". Inclusion criteria include cohorts from the last 10 years of the BrS population with the aVR sign as a predictor. We excluded patients with channelopathies other than Brugada syndrome and low-quality studies. We assessed the quality of studies using the Newcastle-Ottawa Scale. Data will be presented as odds ratios with 95 % confidence intervals. The endpoint is life-threatening arrhythmia resulting in sudden cardiac death.
resultsFrom 7 cohort studies (1763 patients), R-wave amplitude ≥3 mV in lead aVR has increased risk of sudden cardiac death (OR = 2.15, 95 % CI = 1.56-2.98, I
conclusionaVR sign can predict sudden cardiac death in Brugada syndrome and this marker may be considered for risk assessment and lead the management strategy for better prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.